Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 24 2025
0mins
Source: Globenewswire
Clinical Trial Results: Adagene Inc. reported a 33% overall response rate in its Phase 2 trial of ADG126 for microsatellite stable colorectal cancer, with plans to expand the study to include patients with liver metastases and earlier lines of therapy.
Financial Overview: The company has a cash balance of $85.2 million, expected to fund operations into late 2026, while reporting a net loss of $33.4 million for 2024, reflecting a focus on research and development of its SAFEbody technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
